Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials
暂无分享,去创建一个
T. Bousema | M. Niemi | C. Drakeley | U. d’Alessandro | S. Sirima | K. Lanke | M. Affara | J. Okebe | Edith C. Bougouma | A. Tiono | B. Gonçalves | J. Bradley | A. Ouédraogo | G. Bastiaens | S. Coulibaly | H. Pett | G. Sanou | I. Nebie’ | Bronner P. Gonçalves | Helmi E Pett | Joseph Okebe
[1] J. Ndiaye,et al. Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] Hannah C. Slater,et al. Mathematical Modelling to Guide Drug Development for Malaria Elimination , 2017, Trends in parasitology.
[3] A. Dicko,et al. Comparison of molecular quantification of Plasmodium falciparum gametocytes by Pfs25 qRT-PCR and QT-NASBA in relation to mosquito infectivity , 2016, Malaria Journal.
[4] B. Ngasala,et al. Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania , 2016, Malaria Journal.
[5] A. Dicko,et al. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. , 2016, The Lancet. Infectious diseases.
[6] F. Nosten,et al. Single Low Dose Primaquine (0.25mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects , 2016, PloS one.
[7] T. Bousema,et al. Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial , 2016, BMC Medicine.
[8] J. Rubio,et al. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial , 2016, Malaria Journal.
[9] I. Elyazar,et al. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia , 2015, BMC Medicine.
[10] Emmaculate Lum,et al. Malarial Anaemia and Anaemia Severity in Apparently Healthy Primary School Children in Urban and Rural Settings in the Mount Cameroon Area: Cross Sectional Survey , 2015, PloS one.
[11] T. Bousema,et al. The gametocytocidal efficacy of primaquine in malaria asymptomatic carriers treated with dihydroartemisinin-piperaquine in The Gambia (PRINOGAM): study protocol for a randomised controlled trial , 2015, Trials.
[12] B. Tekwani,et al. Differential CYP 2D6 Metabolism Alters Primaquine Pharmacokinetics , 2015, Antimicrobial Agents and Chemotherapy.
[13] T. Bousema,et al. Glucose-6-Phosphate Dehydrogenase Status and Risk of Hemolysis in Plasmodium falciparum-Infected African Children Receiving Single-Dose Primaquine , 2014, Antimicrobial Agents and Chemotherapy.
[14] J. Crump,et al. Evaluation of In-Hospital Management for Febrile Illness in Northern Tanzania before and after 2010 World Health Organization Guidelines for the Treatment of Malaria , 2014, PloS one.
[15] T. Bousema,et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. , 2014, The Lancet. Infectious diseases.
[16] J. Swen,et al. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. , 2014, Current drug metabolism.
[17] David L. Smith,et al. Modeling Within-Host Effects of Drugs on Plasmodium falciparum Transmission and Prospects for Malaria Elimination , 2014, PLoS Comput. Biol..
[18] Q. Cheng,et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests , 2013, Malaria Journal.
[19] D. Caridha,et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6 , 2013, Malaria Journal.
[20] D. Caridha,et al. An in vivo drug screening model using glucose-6-phosphate dehydrogenase deficient mice to predict the hemolytic toxicity of 8-aminoquinolines. , 2013, The American journal of tropical medicine and hygiene.
[21] L. Okell,et al. Malaria transmission after artemether-lumefantrine and dihydroartemisinin-piperaquine: a randomized trial. , 2013, The Journal of infectious diseases.
[22] T. Bousema,et al. Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda , 2013, BMJ Open.
[23] N. White. Primaquine to prevent transmission of falciparum malaria. , 2013, The Lancet. Infectious diseases.
[24] I. Elyazar,et al. Randomized, Open-Label Trial of Primaquine against Vivax Malaria Relapse in Indonesia , 2012, Antimicrobial Agents and Chemotherapy.
[25] T. Bousema,et al. Rationale for short course primaquine in Africa to interrupt malaria transmission , 2012, Malaria Journal.
[26] A. Gaedigk,et al. CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes. , 2012, Pharmacogenetics and genomics.
[27] Q. Bassat,et al. Tolerability and Safety of Primaquine in Papua New Guinean Children 1 to 10 Years of Age , 2012, Antimicrobial Agents and Chemotherapy.
[28] S. Hoffman,et al. Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue , 2011, Proceedings of the National Academy of Sciences.
[29] S. Duparc,et al. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials , 2011, Malaria Journal.
[30] T. Déirdre Hollingsworth,et al. The Potential Contribution of Mass Treatment to the Control of Plasmodium falciparum Malaria , 2011, PloS one.
[31] Teun Bousema,et al. Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and Elimination , 2011, Clinical Microbiology Reviews.
[32] David Schellenberg,et al. A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics , 2011, PLoS medicine.
[33] Elizabeth Ashley,et al. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial , 2010, The Lancet. Infectious diseases.
[34] Teun Bousema,et al. Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs , 2010 .
[35] T. Bousema,et al. In Tanzania, Hemolysis after a Single Dose of Primaquine Coadministered with an Artemisinin Is Not Restricted to Glucose-6-Phosphate Dehydrogenase-Deficient (G6PD A−) Individuals , 2010, Antimicrobial Agents and Chemotherapy.
[36] F. Ou,et al. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine , 2010, Malaria Journal.
[37] T. Bousema,et al. Substantial Contribution of Submicroscopical Plasmodium falciparum Gametocyte Carriage to the Infectious Reservoir in an Area of Seasonal Transmission , 2009, PloS one.
[38] A. Dicko,et al. Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria. , 2009, The American journal of tropical medicine and hygiene.
[39] Paul Garner,et al. Artemisinin-based combination therapy for treating uncomplicated malaria. , 2009, The Cochrane database of systematic reviews.
[40] S. Blair,et al. [Therapeutic efficacy of a regimen of artesunate-mefloquine-primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development]. , 2009, Biomedica : revista del Instituto Nacional de Salud.
[41] Pardis C Sabeti,et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility , 2009, European Journal of Human Genetics.
[42] Teun Bousema,et al. Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials , 2008, Malaria Journal.
[43] A. Gaedigk,et al. The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype , 2008, Clinical pharmacology and therapeutics.
[44] H. Babiker,et al. A Randomized Open-Label Trial of Artesunate- Sulfadoxine-Pyrimethamine with or without Primaquine for Elimination of Sub-Microscopic P. falciparum Parasitaemia and Gametocyte Carriage in Eastern Sudan , 2007, PloS one.
[45] T. Bousema,et al. Primaquine Clears Submicroscopic Plasmodium falciparum Gametocytes that Persist after Treatment with Sulphadoxine-Pyrimethamine and Artesunate , 2007, PloS one.
[46] Ernest Beutler,et al. Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development. , 2007, The American journal of tropical medicine and hygiene.
[47] S. Hoffman,et al. Primaquine therapy for malaria. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] Petra Schneider,et al. Quantification of Plasmodium falciparum gametocytes in differential stages of development by quantitative nucleic acid sequence-based amplification. , 2004, Molecular and biochemical parasitology.
[49] N. Gogtay,et al. A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India , 2004, Annals of tropical medicine and parasitology.
[50] Nicholas J. White,et al. Activities of Artesunate and Primaquine against Asexual- and Sexual-Stage Parasites in Falciparum Malaria , 2004, Antimicrobial Agents and Chemotherapy.
[51] P. Kager,et al. CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone–proguanil against falciparum malaria in Vietnam , 2004, Tropical medicine & international health : TM & IH.
[52] Y. Suputtamongkol,et al. The efficacy of combined mefloquine-artesunate versus mefloquine-primaquine on subsequent development of Plasmodium falciparum gametocytemia. , 2003, The American journal of tropical medicine and hygiene.
[53] R. Price,et al. Factors contributing to anemia after uncomplicated falciparum malaria. , 2001, The American journal of tropical medicine and hygiene.
[54] C. Drakeley,et al. Artesunate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. , 2001, The Journal of infectious diseases.
[55] K. Yip. Antimalarial work in China: a historical perspective. , 1998, Parassitologia.
[56] S. Hoffman,et al. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. , 1995, The Journal of infectious diseases.
[57] E. Beutler,et al. Frequency of glucose-6-phosphate dehydrogenase (G6PD) mutations in Chinese, Filipinos, and Laotians from Hawaii , 1993, Human Genetics.
[58] P. Reeve,et al. Acute intravascular haemolysis in Vanuatu following a single dose of primaquine in individuals with glucose-6-phosphate dehydrogenase deficiency. , 1992, The Journal of tropical medicine and hygiene.
[59] K. Thimasarn. Current measures of containment of multi-drug resistant falciparum malaria in Thailand. , 1992, The Southeast Asian journal of tropical medicine and public health.
[60] R S Galen,et al. Application of the predictive value model in the analysis of test effectiveness. , 1982, Clinics in laboratory medicine.
[61] K. K. Khoo. The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. , 1981, Annals of tropical medicine and parasitology.
[62] T. Harinasuta,et al. EFFECT OF PRIMAQUINE ON GAMETOCYTES OF PLASMODIUM FALCIPARUM IN THAILAND , 1980, The Lancet.
[63] R. Galen,et al. The predictive value of serum haptoglobin in hemolytic disease. , 1980, JAMA.
[64] J. Kaplan,et al. International Committee for Standardization in Haematology: Recommended Screening Test for Glucose‐6‐Phosphate Dehydrogenase (G‐6‐PD) Deficiency , 1979, British journal of haematology.
[65] H. Notopuro,et al. Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.
[66] R. J. Dern,et al. The hemolytic effect of primaquine. IV. The relationship of cell age to hemolysis. , 1954, The Journal of laboratory and clinical medicine.
[67] E. Ashley,et al. Primaquine: the risks and the benefits , 2014, Malaria Journal.
[68] A. Kleinman,et al. Primaquine Failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria , 2013 .
[69] Q. Cheng,et al. PD testing in support of treatment and elimination of malaria : recommendations for evaluation of G 6 PD tests , 2013 .
[70] A. Kondrashin,et al. [Widespread use of primaquine for control of Plasmodium vivax epidemics in a population with varying degrees of G6PD deficiency]. , 2010, Meditsinskaia parazitologiia i parazitarnye bolezni.
[71] R. J. Dern,et al. The hemolytic effect of primaquine V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. , 1981, The Journal of laboratory and clinical medicine.
[72] D. Clyde. Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. , 1981, Bulletin of the World Health Organization.
[73] A. Gehani,et al. [G6PD deficiency]. , 1974, Xianggang hu li za zhi. The Hong Kong nursing journal.
[74] Resistance to Antimalarials. Chemotherapy of malaria and resistance to antimalarials. Report of a WHO scientific group. , 1973, World Health Organization technical report series.
[75] E. Beutler,et al. Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. , 1968, Blood.
[76] K. Abeyaratne,et al. Sensitivity to primaquine in Ceylonese children due to deficiency of erythrocytic glucose-6-phosphate dehydrogenase. , 1968, The Ceylon medical journal.
[77] D. Clyde. Mass administration of an antimalarial drug combining 4-aminoquinoline and 8-aminoquinoline in Tanganyika. , 1962, Bulletin of the World Health Organization.
[78] R. W. Burgess,et al. The effect of a single dose of primaquine on the gametocytes, gametogony and sporogony of Laverania falciparum. , 1961, Bulletin of the World Health Organization.
[79] A. Tarlov,et al. Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report. , 1960, Bulletin of the World Health Organization.
[80] A. Tarlov,et al. Methaemoglobin reduction test: a new, simple, in vitro test for identifying primaquine-sensitivity. , 1960, Bulletin of the World Health Organization.
[81] L. Bruce-Chwatt. Malaria research and eradication in the USSR. A review of Soviet achievements in the field of malariology. , 1959, Bulletin of the World Health Organization.
[82] R. J. Dern,et al. The hemolytic effect of primaquine. V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. , 1955, The Journal of laboratory and clinical medicine.
[83] C. Clayman,et al. Toxicity of primaquine in Negroes. , 1952, Journal of the American Medical Association.